Reversal of Phen-Fen associated valvular regurgitation documented by serial echocardiography

Journal of the American Society of Echocardiography

Volumn 15, Issue 6, 2002, Pages 653-657

  Vagelos, Randall ^a,b,c   Jacobs, Michael ^a,b   Popp, Richard L ^a,b   Liang, David ^a,b  

^a Stanford University School of Medicine ^*

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN; ENALAPRIL; FENFLURAMINE; HYDROCHLOROTHIAZIDE PLUS TRIAMTERENE; PHENTERMINE; ANOREXIGENIC AGENT;

ADULT; AORTA VALVE REGURGITATION; ARTICLE; BORDERLINE HYPERTENSION; CARDIAC PATIENT; CASE REPORT; DISEASE SEVERITY; DOPPLER FLOWMETRY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; EPIGASTRIC PAIN; FEMALE; FOLLOW UP; HEART ATRIUM ENLARGEMENT; HEART SIZE; HEART SUPRAVENTRICULAR ARRHYTHMIA; HUMAN; LOW DRUG DOSE; MITRAL VALVE REGURGITATION; OBESITY; PHYSICAL EXAMINATION; REMISSION; SUPRAVENTRICULAR TACHYCARDIA; WEIGHT GAIN; WEIGHT REDUCTION; CHEMICALLY INDUCED DISORDER; CONVALESCENCE; ECHOGRAPHY; MIDDLE AGED; VALVULAR HEART DISEASE;

APPETITE DEPRESSANTS; ECHOCARDIOGRAPHY; FEMALE; FENFLURAMINE; HEART VALVE DISEASES; HUMANS; MIDDLE AGED; PHENTERMINE; RECOVERY OF FUNCTION;

EID: 0036597684     PISSN: 08947317     EISSN: None     Source Type: Journal    
DOI: 10.1067/mje.2002.117864     Document Type: Article

References (20)

1. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Eng J Med 1997;337:581-8.
2. Perry GJ, Helmcke F, Nanda NC, Byard C, Soto B. Evaluation of aortic insufficiency by Doppler color flow mapping. J Am Coll Cardiol 1987;9:952-9.
3. Helmcke F, Nanda NC, Hsiung MC, Soto B, Adey CK, Goyal RG, et al. Color Doppler assessment of mitral regurgitation with orthogonal planes. Circulation 1987;75:175-83.
4. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: US Department of Health and Human Services interim public health recommendations, November 1997. MMWR Morb Mortal Wkly Rep 1997;46:1061-6.
5. Jollis JG, Landolfo CK, Kisslo J, Constantine GD, Davis KD, Ryan T. Fenfluramine and phentermine and cardiovascular findings. Effect of treatment duration and prevalence of valve abnormalities. Circulation 2000;101:2071-7.
6. Weissman NJ, Tighe JF Jr, Gottdiener JS, Gwynne JT. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. N Engl J Med 1998;339:725-32.
7. Kahn MA, Herzog CA, St Peter JV, Hartley GG, Madlon-Kay R, Dick CD, et al. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med 1998;339:713-8.
8. Jick H, Vasilakis C, Weinrauch LA, Meier CR, Jick SS, Derby LE. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Fngl J Med 1998;339:719-24.
9. Burger AJ, Sherman HB, Charlamb MJ, Kim J, Asinas LA, Flickner SR, et al. Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months. J Am Coll Cardiol 1999;34:1153-8.
10. Shively BK, Roldan CA, Gill EA, Najarian T, Loar SB. Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine. Circulation 1999;100:2161-7.
11. Gardin J, Schurmacher D, Constantine G, Davis KD, Leung C, Reid CL. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA 2000;283:1703-9.
12. Kimmel SE, Keane MG, Crary JL, Jones J, Kinman JL, Beare J, et al. Detailed examination of fenfluramine-phentermine users with valve abnormalities identified in Fargo, North Dakota. Am J Cardiol 1999;84:304-8.
13. Wee CC, Phillips RS, Aurigemma G, Erban S, Kriegel G, Riley M, et al. Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication. Ann Intern Med 1998;129:870-4.
14. Weissman NJ, Tighe JF Jr, Gottdeiner JS, Gwynne JT. Prevalence of valvular-regurgitation associated with dexfenfluramine 3 to 5 months after discontinuation of treatment. J Am Coll Cardiol 1999;34:2088-95.
15. Weissman NJ, Panza JA, Tighe JF Jr, Gwynne JT. Natural history of valvular regurgitation 1 year after discontinuation of dexfenfluramine therapy: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;134:267-73.
16. Hensrud DD, Connolly HM, Grogan M, Miller FA, Bailey KR, Jensen MD. Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine. Mayo Clin Proc 1999;74:1191-7.
17. Mast ST, Jollis JG, Ryan T, Anstrom KJ, Crary JL. The progression of fenfluramine-associated valvular heart disease assessed by echocardiography. Ann Intern Med 2001;134:261-6.
18. Kimmel SF, Keane MG, Crary JL, Jones J, Kinman JL, Beare I, et al. Detailed examination of fenfluramine-phentermine users with valve abnormalities identified in Fargo, North Dakota. Am J Cardiol 1999;84:304-8.
19. Cannistra LB, Cannistra AJ. Regression of multivalvular regurgitation after the cessation of fenfluramine and phentermine treatment [letter to the editor]. N Engl J Med 1998;339:771.
20. Firstenberg MS, Thomas JD, Garcia MJ. Resolution of phentermine- fenfluramine induced valvular regurgitation. Cardiovascular Fellows Forum 2000;2:3-4.